Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Curr Alzheimer Res. 2010 May;7(3):200-6.

Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.

Author information

  • 1Department of Pathology, Waisman Center for Developmental Disabilities, UWMadison, WI, USA. jsmalter@wisc.edu


As the mechanisms underlying neuronal development and degeneration become clarified, a number of common effectors and signaling pathways are becoming apparent. Here we describe the identification of Abeta, long considered a pathologic mediator of Alzheimers Disease and Down Syndrome, as similarly over-expressed in the neurodevelopmental disease, Fragile X Syndrome. We also show that mGluR5 inhibitors, currently employed for the treatment of Fragile X, reduce Abeta production in rodent models of Fragile X and AD as well as reduce disease phenotypes including seizures. Thus seemingly disparate neurologic diseases may share a common pathologic instigator and be treatable with a common, currently available class of therapeutics.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk